Immune Pharmaceuticals Initiates Phase II Studies of Bertilimumab for Ulcerative Colitis and Bullous Pemphigoid

Immune Pharmaceuticals Initiates Phase II Studies of Bertilimumab for Ulcerative Colitis and Bullous Pemphigoid
Immune Pharmaceuticals Inc., a company currently developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer, recently announced the initiation of a Phase II Ulcerative Colitis trial and the schedule of the initiation of a Phase II Bullous Pemphigoid trial on July 1, 2015. The initiation of the study allows for patient screening and enrollment into the study upon selection. Paul I. Nadler, MD, FCP, FACP Executive Vice President, R&D and Chief Medical Officer of Immune Pharmaceuticals, commented in a recent press release, "We believe that bertilimumab is a promising first in class monoclonal antibody with the potential to treat multiple inflammatory diseases. It targets eotaxin-1, which is also a biomarker of disease severity, supporting a personalized medicine and companion diagnostic strategy. The first two Phase II clinical trials with bertilimumab in Bullous Pemphigoid and Ulcerative Colitis are expected to provide guidance on further clinical development." The Phase II Ulcerative Colitis study of bertilimumab is a double blind placebo controlled clinical study involving 42 patients, who suffer from moderate to severe Ulcerative Colitis (UC), a chronic condition causing ulcers and inflammation in the digestive tract. According to a Global Data Report, the condition affects about 2 million people worldwide. The study endpoints include the efficacy and safety assessed through decr
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *